Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims: To assess the effect of LY2409021 on systolic blood pressure ( SBP ) in patients with type 2 diabetes. Materials and methods: This 6‐week, randomized, crossover study evaluated the effects of once‐daily administration of LY2409021 20 mg vs those of placebo on SBP , diastolic BP ( DBP ), and mean arterial pressure ( MAP ) using 24‐hour ambulatory BP monitoring ( ABPM ) in 270 subjects treated with diet/exercise ± metformin. Other measures included changes in glycemic control, serum lipids, and hepatic safety markers. Results: At 6 weeks of LY2409021 treatment, 24‐hour mean SBP was increased, with a least squares mean ( LSM ) difference of 2.26 mm H g vs placebo (95% CI : 1.11, 3.40; P < .001). The 24‐hour mean DBP and MAP also increased, with LSM differences of 1.37 mm H g (95% CI : 0.66, 2.08; P < .001) and 1.67 mm H g (95% CI : 0.86, 2.47; P < .001) vs placebo, respectively. At week 6, LY2409021 treatment reduced glycated hemoglobin ( HbA1c ) levels, with an LSM difference of −0.49% (−5.4 mmol/mol) (95% CI : −0.56%, −0.42% [−6.1, −4.6 mmol/mol]; P < .001) vs placebo. Mean HbA1c at baseline was 7.3% (56 mmol/mol). Small but significant changes in serum lipid and aminotransferase levels were observed with LY2409021 treatment (all P < .05 vs placebo). Conclusions: Statistically significant increases in BP , MAP and serum lipid levels were observed with LY2409021 treatment at a dose that lowered HbA1c and glucose levels. These effects may limit the clinical utility of LY2409021 as a chronic treatment for type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension
Clement, D. L., De Buyzere, M. L., De Bacquer, D. A., de Leeuw, P. W., Duprez, D. A., Fagard, R. H., Gheeraert, P. J., Missault, L. H., Braun, J. J., Six, R. O., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022273 · Cited by 1,085 · cited 2×
“78) over 5 years.(23) The Framingham risk calculator(24) shows that a 3 mm”
BackgroundGlucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Shah, P., Vella, A., Basu, A., Basu, R., Schwenk, W. F., & Rizza, R. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6993 · Cited by 368
Kelly, R. P., Garhyan, P., Raddad, E., Fu, H., Lim, C. N., Prince, M. J., Pinaire, J. A., Loh, M. T., & Deeg, M. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12446 · Cited by 110
Self-citation
Cited by
Current anti-diabetic agents and their molecular targets: A review
Kerru, N., Singh-Pillay, A., Awolade, P., & Singh, P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.061 · Cited by 369
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis
Perry, R. J., Zhang, D., Guerra, M. T., Brill, A. L., Goedeke, L., Nasiri, A. R., Rabin-Court, A., Wang, Y., Peng, L., Dufour, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2074-6 · Cited by 186
Guzman, C. B., Zhang, X. M., Liu, R., Regev, A., Shankar, S., Garhyan, P., Pillai, S. G., Kazda, C., Chalasani, N., & Hardy, T. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12958 · Cited by 172
“Elevations in blood pressure observed for LY2409021 support findings from a separate ambulatory blood pressure monitoring study with LY2409021.(8) Moreover, increases in blood pressure have also been observed with MK-0893 and PF-06291874.”
BackgroundMethodInfluentialSelf-citationThe Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“The effect was dose related: the more the receptor was inhibited, the greater the hyperse-cretion of glucagon 184 .”
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
Metadata
- Authors
- Kazda, C. M., Frias, J., Foga, I., Cui, X., Guzman, C. B., Garhyan, P., Heilmann, C., Yang, J. A., & Hardy, T. A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-03-27
- Volume
- 19
- Issue
- 8
- Pages
- 1071-1077
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2588151434
- Cited by
- 39
- References
- 6
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.